Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2008-01-15
2008-01-15
Brusca, John S (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C435S006120, C435S007100
Reexamination Certificate
active
07319933
ABSTRACT:
The present invention provides a novel method for determining the biological activity of a compound comprising the steps of a) contacting a host with a compound; b) determining the general transcriptional gene response of the host; and c) quantitating the general transcriptional gene response induced by said compound.
REFERENCES:
patent: 5837832 (1998-11-01), Chee et al.
patent: 2002/0174096 (2002-11-01), O'Reilly et al.
patent: 0593868 (1998-04-01), None
patent: 0510356 (1999-01-01), None
patent: 0834575 (2001-11-01), None
patent: 0834576 (2002-01-01), None
patent: 0809996 (2003-04-01), None
patent: 1 333 036 (2003-08-01), None
patent: WO96/31622 (1996-10-01), None
patent: WO97/10365 (1997-03-01), None
patent: WO98/30883 (1998-07-01), None
patent: WO02/18633 (2002-03-01), None
patent: WO 02/50306 (2002-06-01), None
patent: WO 02/090927 (2002-11-01), None
patent: WO 2004/045545 (2004-06-01), None
Kumar-Sinha Molecular Cross-tlak between the TRAIL and Interferon Signalling Pathways. Journal of Biological Chemistry, vol. 277, pp. 575-585 (2002.
Turri et al. Characterisation of a novel minisatellite that provides multiple splice donor sites in an interferon-induced transcript. Nucleic Acids Research vol. 23, pp. 1854-1861 (1995).
Certa et al. High density oligonucleotide array analysis of interferon-alpha2a sensitivity and transcriptional response in melanoma cells. British Journal of Cancer vol. 85, pp. 107-114 (2001).
GenBank Accession No. U22970 [online] [retrieved on Sep. 16, 2006]. Retrieved from the Internet : http:/
cbi.nlm.nih.gov/entrez/viewer.fcg?db=nucleotide&val-881920.
Komor et al. Transcriptional Profiling of Human Hematopoiesis During In Vitro Lineage-Specific Differentiation. Stem Cells vol. 23, pp. 1154-1169 (2005).
P. Bailon et al., Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol0conjugated Interferon-2a for the treatment of hepatitis C, Bioconjugate Chem. 12 (2001), 195-202.
Z.Z. Chong, et al., Hematopoietic factor erythropoietin foster neuroprotection through novel signal transduction cascades, J. Cereb.Blood Flow Metab., 22 (2002), 503-514.
CK Glass: Some new twists in the regulation of gene expression by throid hormone and retinoic acid receptors, J. Endorinol, 150 (1996), 349-357.
T. Hanada and A. Yoshimura: Regulation of cytokine signaling and inflammation, Cytokine Growth Factor Rev., 13 (2002), 413-421.
J.M. Harris, et al., Pegylation: A novel process for modifying pharmacokinetics, Clin. Pharmacokinet. 40 (2001), 539-551.
Klaus, et al., J. Mol. Biol. 274 (1997) 661-675.
R. Mandler et al., Modification in syntheses strategy . . . , Bioconjugate Chemistry, 13 (2002), 786-791.
G.S. McKnight: Cyclic AMP second messenger systems, Curr. Opin. Cell Biol., 3 (1991) 213-217.
L. Mulcahy: the erythropoietin receptor, Semin. Oncol. 28 (2001), 19-23.
Y. Nishio, et al., Cilostazol, a cAMP phosphodiesterase inhibitor . . . , Hormone & Metabolic Research, 29 (1997) 491-495.
A. Rowe, Retinoid X Receptors,Int. J. Biochem. Cell Biol. 29 (1997), 275-278.
Y. Sato et al., Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction, Ann. N.Y. Acad. Sci., 902 (2000), 201-207.
J.L. Spivak: The mechanism of action of erythropoietin, Int. J. Cell Cloning, 4 (1986) 139-166.
A.H. Talukder et al, Antihuman epidermal growth factor . . . , Clin. Cancer Res. 8 (2002), 3285-3289.
B. Wagner, et al., 7-Benzylamino-6chloro-2piperazino-4-pyrrolidino-pteridine . . . Biochemical Pharmacology, 63 (2002) 659-668.
D.M. Wojchowski and T.C. He: Signal transduction in the erythropoietin receptor system, Stem. Cells, 11 (1993), 381-392.
Andrew R. Pachner, et al.,MxA Gene Expression Analysis an an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity, Molecular Diagnosis, Mar. 2003, pp. 17-25, vol. 7 (1).
Seth P. Monkarsh, et al.,Positional Isomers of Monopegylated Interferon α-2α: Isolation, Characterization, and Biological Activity, Analytical Biochemistry, May 1, 1997, p. 434-440, vol. 247(2).
S. Foser, et al.,Improved biological and transcriptional activity of monopegylated interferon-α-2α isomers, The Pharmacogenomics Journal, 2003, p. 312-319, vol. 3(6).
Jobst, J., et al., Hepatology, vol. 36, No. 4 (Pt.2), p. 289A, (503) (2002).
Der, S.D., et al., Proc. Natl. Acad. Sci. USA., vol. 95 (26), p. 15623-8 (1998).
Certa Ulrich
Foser Stefan
Weyer Karl
Brusca John S
Hoffmann-La Roche Inc.
Johnston George W.
Tramaloni Dennis P.
LandOfFree
Gene transcription assay method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene transcription assay method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene transcription assay method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2801115